mRNA medicine with or without immunotherapy for advanced solid cancers
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18+ (or 12+ for one melanoma group) and can provide consent/assent before any study steps.
- You have advanced or metastatic cancer that matches one of the study types (such as melanoma, NSCLC, certain bladder/head and neck/colorectal/basal cell/triple-negative breast cancers).
- Your cancer must have measurable disease that can be tracked on scans, and you must have a tumor spot that can be biopsied plus another spot that can be followed for response.
- Your body must be able to tolerate treatment (ECOG status 0–1 and blood/organ tests adequate).
- For groups that involve PD-L1, your tumor must meet a required PD-L1 level (often confirmed with a central test on a biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new mRNA-based vaccines, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the vaccines are safe and can help shrink or control the cancer.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a new mRNA-based treatment injected directly into solid tumors that haven't responded to standard therapy. The goal is to help your immune system recognize and attack cancer cells.
This trial tests a new mRNA vaccine that targets a unique part of your tumor cells, given together with an immunotherapy drug (anti-PD-1). It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.